Dynamed Philadelphia LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$4,741,642	406
2024	Research	$3,209,021	103
2023	Research	$6,057,151	2,536
2022	Research	$1,662,725	26

Breakdown

Who paid Research payments · program years 2022–2025

Moderna TX, Inc. $12,890,621 2,932 payments
Pfizer Inc. $1,730,406 55 payments
Bavarian Nordic A/S $915,768 60 payments
Novavax Inc $115,399 18 payments
Teva Pharmaceuticals USA, Inc. $18,345 6 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $4,497,204 103 payments
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,168,056 65 payments
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $877,198 625 payments
A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $782,655 26 payments
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $756,313 10 payments
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $730,919 2 payments
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $682,979 54 payments
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age $657,720 1,198 payments
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $604,527 18 payments
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age $556,703 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.